Pacira BioSciences Stock Forecast for 2023 - 2025 - 2030
Updated on 05/30/2023
Pacira BioSciences Stock Forecast and Price Target
If the average 2023 price target of $78.00 recently set by six prominent experts for Pacira BioSciences is met, there would be a potential upside of approximately 98.68% from the last closing price in May, 2023. The high estimate is $94.00, and the low is $54.00. If you're not interested in PCRX stock, you may be interested in its competitors.
98.68% Upside
Pacira BioSciences Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's Price has grown, increasing from $45.26 to $81.30 – an increase of 79.64%. For the following year, the 0 analysts predict that Pacira BioSciences's Fair Value will drop by 25.70%, reaching $60.41. In 2030, the professionals' prediction is that PCRX's Fair Value will decrease by 21.44%, reaching $63.87.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$154.37 | Buy/Sell | $178.79 | 16.93% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$37.01 | Buy/Sell | $47.96 | 42.26% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$101.73 | Buy/Sell | $122.59 | 22.87% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$82.50 | Buy/Sell | $90.05 | 4.24% |
| SYK Stock Forecast | Stryker Corp | Outperform |
8
|
$271.50 | Buy/Sell | $308.32 | -4.24% |
Pacira BioSciences Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's Revenue has grown, increasing from $421.03M to $541.53M – an increase of 28.62%. For the following year, the 0 analysts predict that Pacira BioSciences's Revenue will drop by 14.44%, reaching $463.32M. In 2030, the professionals' prediction is that PCRX's Revenue will decrease by 13.01%, reaching $471.09M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$50.51 | Buy/Sell | $52.51 | -1.01% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.33 | Buy/Sell | $60.73 | 43.81% |
| TFX Stock Forecast | Teleflex | Hold |
13
|
$232.11 | Buy/Sell | $260.07 | 9.86% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMBU B Stock Forecast | Ambu A/S | Hold |
18
|
kr65.76 | Buy/Sell | kr94.25 | 45.23% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$10.76 | Buy/Sell | $12.60 | 16.17% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$33.27 | Buy/Sell | $35.50 | 2.19% |
Pacira BioSciences Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's Free Cash Flow has grown by 45.66%, from $60.36M to $87.92M. According to the 0 analysts polled, in the next year, Pacira BioSciences's Free Cash Flow will fall by 18.97%, reaching $71.24M. By 2030, professionals believe that Pacira BioSciences's Free Cash Flow will have decreased by 17.29%, falling to $72.72M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AVNS Stock Forecast | Avanos Medical | Hold |
11
|
$23.95 | Buy/Sell | $43.00 | 44.05% |
| MNKP.F Stock Forecast | Mallinckrodt | - |
12
|
$19.00 | Buy/Sell | $1.50 | 9.11% |
| COLL Stock Forecast | Collegium Pharmaceutical | Buy |
11
|
$22.53 | Buy/Sell | $27.50 | 28.72% |
Pacira BioSciences Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's Net Income has grown, increasing from $-11.02M to $41.98M – a growth of 480.94%. The next year looks promising for Pacira BioSciences, with analysts predicting Net Income of $95.95M – an increase of 128.57%. Over the next nine years, experts anticipate that Pacira BioSciences's Net Income will grow at a rate of 219.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NasdaqGS:BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | Buy/Sell | $10.00 | 78.89% |
| ANIP Stock Forecast | ANI Pharmaceuticals | Outperform |
13
|
$46.15 | Buy/Sell | $61.67 | -2.49% |
| ASRT Stock Forecast | Assertio Holdings | Outperform |
8
|
$5.51 | Buy/Sell | $5.83 | 8.89% |
Pacira BioSciences EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's EBITDA has grown from $55.29M to $161.38M – a 191.88% increase. For the next year, 0 analysts project Pacira BioSciences's EBITDA to drop by 44.78%, reaching $89.11M. By 2030, professionals believe that Pacira BioSciences's EBITDA will decrease by 32.65%, reaching $108.69M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACRX Stock Forecast | AcelRx Pharmaceuticals | Outperform |
6
|
$0.29 | Buy/Sell | $4.25 | 1279.31% |
| AQST Stock Forecast | Aquestive Therapeutics | Outperform |
0
|
$2.93 | Buy/Sell | $0.00 | 241.30% |
| TRVN Stock Forecast | Trevena | Outperform |
2
|
$1.29 | Buy/Sell | $5.18 | 171.32% |
Pacira BioSciences EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's EBIT has grown by 272.00%, rising from $35.71M to $132.84M. According to 0 prominent analysts, Pacira BioSciences's EBIT will fall by 51.11% in the next year, reaching $64.94M. By 2030, professionals believe that Pacira BioSciences's EBIT will decrease by 34.86%, reaching $86.54M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.23 | Buy/Sell | $0.00 | 10.76% |
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.45 | Buy/Sell | $5.00 | 11.11% |
| BXRX Stock Forecast | Baudax Bio | Buy |
0
|
$0.74 | Buy/Sell | $0.00 | 981.08% |
Pacira BioSciences EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Pacira BioSciences's EPS has grown, increasing from $1.67 to $3.00 – an increase of 79.64%. For the following year, the 0 analysts predict that Pacira BioSciences's EPS will drop by 25.70%, reaching $2.23. In 2030, the professionals' prediction is that PCRX's EPS will decrease by 21.44%, reaching $2.36.
Site Navigation
.jpg)